**Abstracts**

**EP336/#1095 DEVELOPING A CENTRAL DATABASE AND VIRTUAL BIOBANK FOR RARE GYNAECOLOGICAL CANCERS IN THE UK: RANGO (RARE NEOPLASMS OF GYNAECOLOGICAL ORIGIN)**

1Marcia Hall*, 2John Magnare, 3Rosaidi Glasspool, 4Jayaroban Jayneeth, 5Rebecca Herbertson, 6Rebecca Bowen, 7Sayed Saravi, 8Phillip Rolland, 9Isaime Miler, 10Thiera Modanah, 11Emmanouil Karteris. 1Mount vernon Cancer Centre, Medical Oncology, Northwood, UK; 2Royal Cornwall Hospital NHS Trust, Oncology, TR LJ, UK; 3Beatson West of Scotland Cancer Centre and Institute of Cancer Sciences, University of Glasgow, and NCR, Medical Oncology, Glasgow, UK; 4Brunel University London, Life Sciences, Uxbridge, UK; 5Brighton and Sussex University NHS Trust, Oncology, Brighton, UK; 6Royal United Hospital Bath, Oncology, Bath, UK; 7Cheltenham General Hospital NHS Trust, Gynaecology, Cheltenham, UK; 8Belfast Health and Social Care Trust, Oncology, Belfast, UK; 9Mount vernon Cancer Centre, Sor, Northwood, UK

**Objectives** To create a platform for further exploration of the diagnosis and current management of patients with RaNGO. To build a tissue bank for future translational work.

**Methods** A clinical trial was devised to collect patient data about a specific set of RaNGO, particularly those where there is unmet clinical need. The trial began recruitment in 2017 and has gradually been opening more gynaecological cancer centre sites across the UK. Patients are requested to consent to disclosure of anonymised details of their diagnosis and treatment as well as follow up information, internationally. They also agree to donate any tissue for future ethically approved laboratory work, nationally or internationally. Some patients also agreed to donate regular blood samples for the identification of circulating factors.

**Results** 354 patients have been recruited from 30 sites. Table 1 shows the set of RaNGO eligible for inclusion and the numbers of patients collected to May 2022. For those who had sequential blood sampling before, during and after treatment, the numbers of cytokeratin +(CK+) cells identified in blood samples reduced following successful treatment and rose with relapsed disease.

**Conclusions** There is considerable enthusiasm for collaboration amongst patients and clinicians to improve the understanding and management of patients with RaNGO. It is hoped that in due course this data can be encompassed in larger international datasets which are likely to be required for meaningful interpretation for the rarest malignancies. Interrogation of blood from patients at more advanced stages continues and will be compared with available tissue.

---

**EP337/#976 CYSTIC MATURE TERATOMA OF THE OVARY WITH MALIGNANT TRANSFORMATION: DIAGNOSTIC AND PROGNOSTIC FEATURES**

1Ons Kaabia*, 2Nihed Abdessayed, 1Rim Bouchahda, 1Mohamed Ben Abdesslem, 1Riadh Ncibi, 2Nihed Abdessayed, 1Rim Bouchahda, 1Mohamed Ben Abdesslem, 1Ons Kaabia*, 2Nihed Abdessayed, 1Rim Bouchahda, 1Mohamed Ben Abdesslem, 1Université de Sousse, Faculté de Médecine de Sousse, Gynecology Obstetrics, Sousse, Tunisia; 2Université de Sousse, Faculté de Médecine de Sousse, Pathology, Sousse, Tunisia

**Objectives** The main objective of this study is to describe the particularities of the diagnosis of the cystic mature teratoma of the ovary with malignant transformation (CMTOWMT). The secondary objective is to identify the prognostic factors of these rare tumors.

**Methods** This is a descriptive longitudinal study carried out over a 20-year period (2000-2019) on all the patients with CMTOWMT, diagnosed in our institution and listed in the center’s cancer registry. For the pathological definitions of the CMTOWMT, we adopted the 2020 world health organization (WHO) classification of tumors of the female genital tract. The CMTOWMT was pathologically defined as malignant tumors developed from a mature tissue element present in the cystic mature teratoma.

**Results** We collected 4680 cases of ovarian tumors of whom 6 cases were CMTOWMT with a frequency of 0.12%. The CMTOWMT represents 4.4% of ovarian cancers and 9.6% of the malignant germ cell tumors of the ovary. The median age of the patients was 57.5 years [44–71] and 66.6% of the patients were menopausal. The mean tumor size was 151.1 mm [110–250]. The pathological diagnosis of the malignant transformation were: 3 squamous cell carcinomas, a thyroid vesicular carcinoma, an adenocarcinoma of the colonic intestinal type, and a primary melanoma. The treatment was a conservative fertility-sparing surgery in 2 non-menopausal patients with early-stage Ia. The intraoperative incidents were dominated by the accidental rupture of the cyst in and the extravasation of its contents (4 cases). Three patients are dead within the first year of follow-up.

**Conclusions** The CMTOWMT is a rare ovarian malignant tumor with a poor prognosis among menopausal women.